Publication
Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil
| Summary: | Abstract Background Genetic factors can be responsible for part of the populational and interindividual differences observed in warfarin users. Objectives To identify occurrence of polymorphisms of the CYP2C9 and VKORC1 genes in patients taking warfarin and relate these profiles to their medication dosages and the Time in Therapeutic Range (TTR). Methods Monthly interviews were conducted for data collection. Data were collected on demographic characteristics and medications in use, especially warfarin, including reason for prescription and weekly dose. TTR was calculated as the percentage of days with international normalized ratio (INR) between 2 and 3. The CYP2C9 and VKORC1 genes were analyzed at a Human Genetics Laboratory. Results 49 patients (74.2%) had polymorphisms of the CYP2C9 and/or VKORC1 genes; the remaining 17 (25.8%) did not have these polymorphisms. The average weekly dose of warfarin was lower among those who had a polymorphism for any of the genes compared to those who did not, with a significant difference (p = 0.035). The mean TTR was also lower among patients with polymorphism. However, the difference between the two groups was not significant for this variable (p = 0.438). Conclusions An association was observed between the polymorphisms and the warfarin doses taken by the patients. However, there was no association with adverse events or the time spent within the therapeutic range in this sample. |
|---|---|
| Main Authors: | Colet,Christiane |
| Other Authors: | Botton,Mariana Rodrigues; Schwambach,Karin Hepp; Amador,Tânia Alves; Heineck,Isabela |
| Subject: | warfarin genetic polymorphism adverse effects |
| Year: | 2021 |
| Country: | Brazil |
| Document type: | article |
| Access type: | open access |
| Associated institution: | IBICT |
| Language: | English |
| Origin: | Oasisbr |
| _version_ | 1871507971160145920 |
|---|---|
| author | Colet,Christiane |
| author2 | Botton,Mariana Rodrigues Schwambach,Karin Hepp Amador,Tânia Alves Heineck,Isabela |
| author2_role | author author author author |
| author_facet | Colet,Christiane Botton,Mariana Rodrigues Schwambach,Karin Hepp Amador,Tânia Alves Heineck,Isabela |
| author_role | author |
| country_str | BR |
| creators_json_txt | [{\"Person.name\":\"Colet,Christiane\"},{\"Person.name\":\"Botton,Mariana Rodrigues\"},{\"Person.name\":\"Schwambach,Karin Hepp\"},{\"Person.name\":\"Amador,Tânia Alves\"},{\"Person.name\":\"Heineck,Isabela\"}] |
| datacite.creators.creator.creatorName.fl_str_mv | Colet,Christiane Botton,Mariana Rodrigues Schwambach,Karin Hepp Amador,Tânia Alves Heineck,Isabela |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.subjects.subject.fl_str_mv | warfarin genetic polymorphism adverse effects |
| datacite.titles.title.fl_str_mv | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| dc.creator.none.fl_str_mv | Colet,Christiane Botton,Mariana Rodrigues Schwambach,Karin Hepp Amador,Tânia Alves Heineck,Isabela |
| dc.format.none.fl_str_mv | text/html |
| dc.identifier.none.fl_str_mv | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492021000100308 |
| dc.language.none.fl_str_mv | eng |
| dc.publisher.none.fl_str_mv | Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.source.none.fl_str_mv | Jornal Vascular Brasileiro v.20 2021 reponame:Jornal Vascular Brasileiro (Online) instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) instacron:SBACV |
| dc.subject.none.fl_str_mv | warfarin genetic polymorphism adverse effects |
| dc.title.fl_str_mv | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_6501 |
| description | Abstract Background Genetic factors can be responsible for part of the populational and interindividual differences observed in warfarin users. Objectives To identify occurrence of polymorphisms of the CYP2C9 and VKORC1 genes in patients taking warfarin and relate these profiles to their medication dosages and the Time in Therapeutic Range (TTR). Methods Monthly interviews were conducted for data collection. Data were collected on demographic characteristics and medications in use, especially warfarin, including reason for prescription and weekly dose. TTR was calculated as the percentage of days with international normalized ratio (INR) between 2 and 3. The CYP2C9 and VKORC1 genes were analyzed at a Human Genetics Laboratory. Results 49 patients (74.2%) had polymorphisms of the CYP2C9 and/or VKORC1 genes; the remaining 17 (25.8%) did not have these polymorphisms. The average weekly dose of warfarin was lower among those who had a polymorphism for any of the genes compared to those who did not, with a significant difference (p = 0.035). The mean TTR was also lower among patients with polymorphism. However, the difference between the two groups was not significant for this variable (p = 0.438). Conclusions An association was observed between the polymorphisms and the warfarin doses taken by the patients. However, there was no association with adverse events or the time spent within the therapeutic range in this sample. |
| dirty | 0 |
| eu_rights_str_mv | openAccess |
| format | article |
| id | oasisbr_145d6f0bfe0c83f83f48da84d4f356fd |
| identifier.url.fl_str_mv | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492021000100308 |
| inst_facet_str | urn:organizationAcronym:oasisbr{{{_:::_}}}IBICT |
| instacron_str | OASISBR |
| institution | IBICT |
| instname_str | IBICT |
| language | eng |
| network_acronym_str | oasisbr |
| network_name_str | Oasisbr |
| oai_identifier_str | oai:scielo:S1677-54492021000100308 |
| organization_str_mv | urn:organizationAcronym:oasisbr |
| person_str_mv | Colet,Christiane Botton,Mariana Rodrigues Schwambach,Karin Hepp Amador,Tânia Alves Heineck,Isabela |
| publishDate | 2021 |
| publisher.none.fl_str_mv | Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) |
| repo_facet_str | urn:repositoryAcronym:oasisbr{{{_:::_}}}Oasisbr |
| reponame_str | Oasisbr |
| repository_id_str | urn:repositoryAcronym:oasisbr |
| service_str_mv | urn:repositoryAcronym:oasisbr |
| spelling | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern BrazilColet,ChristianeBotton,Mariana RodriguesSchwambach,Karin HeppAmador,Tânia AlvesHeineck,Isabelawarfaringenetic polymorphismadverse effectsopen accesshttp://purl.org/coar/access_right/c_abf2http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492021000100308URLhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492021000100308URLHasVersion2021-01-01Abstract Background Genetic factors can be responsible for part of the populational and interindividual differences observed in warfarin users. Objectives To identify occurrence of polymorphisms of the CYP2C9 and VKORC1 genes in patients taking warfarin and relate these profiles to their medication dosages and the Time in Therapeutic Range (TTR). Methods Monthly interviews were conducted for data collection. Data were collected on demographic characteristics and medications in use, especially warfarin, including reason for prescription and weekly dose. TTR was calculated as the percentage of days with international normalized ratio (INR) between 2 and 3. The CYP2C9 and VKORC1 genes were analyzed at a Human Genetics Laboratory. Results 49 patients (74.2%) had polymorphisms of the CYP2C9 and/or VKORC1 genes; the remaining 17 (25.8%) did not have these polymorphisms. The average weekly dose of warfarin was lower among those who had a polymorphism for any of the genes compared to those who did not, with a significant difference (p = 0.035). The mean TTR was also lower among patients with polymorphism. However, the difference between the two groups was not significant for this variable (p = 0.438). Conclusions An association was observed between the polymorphisms and the warfarin doses taken by the patients. However, there was no association with adverse events or the time spent within the therapeutic range in this sample.engtext/htmlSociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)Jornal Vascular Brasileiro v.20 2021reponame:Jornal Vascular Brasileiro (Online)instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)instacron:SBACVjournal articlehttp://purl.org/coar/resource_type/c_6501literatureVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85 |
| spellingShingle | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil Colet,Christiane warfarin genetic polymorphism adverse effects |
| status | SINGLETON |
| status_str | VoR |
| subject.fl_str_mv | warfarin genetic polymorphism adverse effects |
| title | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| title_full | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| title_fullStr | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| title_full_unstemmed | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| title_short | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| title_sort | Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil |
| topic | warfarin genetic polymorphism adverse effects |
| topic_facet | warfarin genetic polymorphism adverse effects |
| url | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492021000100308 |
| visible | 1 |
Funded activities
No funded projects found.